ArticleAging2026
Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration.
Article in Aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hair follicle stem cells (HFSCs) are vital for maintaining hair growth and regeneration. Their dysfunction, often caused by oxidative stress or metabolic imbalance, leads to hair loss and scalp aging. β-catenin is a key protein in the Wnt signaling pathway, and its activity is crucial for HFSC maintenance and regeneration. In this study, we show that methylene blue (MB), a mitochondrial-targeted antioxidant, promotes HFSC proliferation and viability by both reducing reactive oxygen species (ROS) and activating the β-catenin signaling pathway. Functional tests demonstrated that MB significantly sped up wound healing in HFSC cultures, indicating enhanced regenerative ability. Although co-treatment with antioxidants like vitamins A and C improved ROS scavenging, it surprisingly reduced MB-induced β-catenin activation. Conversely, minoxidil, a clinically approved hair growth stimulant, synergized with MB to further activate β-catenin signaling and enhance HFSC viability. Lastly, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) resulted in a dose-dependent decrease in HFSC survival, consistent with emerging reports of treatment-related hair loss. Remarkably, pre-treatment with MB protected HFSCs from GLP-1 RA-induced metabolic stress and premature cell death. Overall, these findings identify methylene blue as a multifunctional therapeutic candidate that reduces oxidative and metabolic stress while supporting HFSC-mediated hair regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.